Myelodysplastic Neoplasms (MDS) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN): New Insights into Diagnosis and Targeted Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 15 July 2026 | Viewed by 625
Editors
Interests: myeloid neoplasms; histiocytic and histiocytic neoplasms; lymphomas; molecular diagnosis; targeted therapy
Special Issues, Collections and Topics in MDPI journals
Interests: myelofibrosis; myelodysplastic syndromes; acute myeloid leukemia; targeted therapy
Special Issue Information
Dear Colleagues,
Myelodysplastic syndromes, newly reclassified as myelodysplastic neoplasms (both abbreviated as MDS), are a heterogeneous group of clonal myeloid neoplasms clinically manifested with peripheral cytopenia, ineffective hematopoiesis, and an increased risk of transformation to acute myeloid leukemia (AML). With the implementation of deep sequencing into routine clinical laboratories, people have better insights into molecular mechanisms of MDS development, highlighting the importance of personalized medicine and targetable therapy. However, an accurate diagnosis of MDS requires a constellation of intensive studies that includes not only histomorphology for dysplasia but also molecular and genetic consulting.
Myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) encompass a broad spectrum of myeloid neoplasms defined by overlapping clinical, histomorphologic, and molecular features of both myelodysplastic and myeloproliferative neoplasms (MDS/MPNs). Clinically, they present with various combinations of cytopenias and cytoses. Chronic myelomonocytic leukemia (CMML) is the most common subtype.
The purpose of this Special Issue is to present new insights into acquired bone marrow failures including MDS and their precursor diseases (e.g., ICUS, CCUS, IDUS), as well as mixed myelodysplastic/myeloproliferative neoplasms, mainly CMML, CMUS, and CCMUS. Pediatric MDS, now termed “MDS of Childhood with low-blasts and high-blasts”, will also be included. Studies related to the harmonization of diagnostic criteria between new WHO and ICC classifications are of particular interest. Cases of MDS and/or MDS/MPNs developing post-cytotoxic therapy are also within the scope of this issue. However, studies on myeloid neoplasms and proliferations associated with antecedent or predisposing conditions—such as Myeloid neoplasms associated with Germline predisposition and Down Syndromes—are not preferred here and will be encouraged for submission to a separate issue.
This Special Issue welcomes both reviews and original research articles. The submission deadline is 15 July 2026.
Dr. Ling Zhang
Dr. David Sallman
Dr. Deniz Peker
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- myelodysplastic syndromes/myelodysplastic neoplasms (MDS)
- myelodysplastic/myeloproliferative neoplasm
- chronic myelomonocytic leukemia (CMML)
- diagnosis
- mutations
- IPSS-R
- IPSS-M
- hypomethylation agents
- targeted therapy
- hematopoietic stem cell transplant (HSCT)
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
